Clinical Trial Update: Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports the completion of a Phase 1/Phase 2 safety study evaluating the combination of gefitinib with radiotherapy in non-metastatic prostate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Gefitinib (Gefitinib)
• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Metastatic Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED